Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-25 @ 2:42 AM
NCT ID:
NCT02184533
Brief Summary:
The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.
Detailed Description:
Primary Objectives:
* To determine the maximum tolerated dose (MTD) of sodium selenite when given in combination with palliative radiation therapy
* To assess the safety and tolerability of the combination of sodium selenite and palliative radiation therapy in metastatic cancer
Secondary Objectives:
* To assess the pharmacokinetics of sodium selenite
* To evaluate the anti tumor activity of sodium selenite and palliative radiation therapy when given in combination
OUTLINE:
Patients receive sodium selenite orally (PO) 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 2 months.
Study:
NCT02184533
Study Brief:
Protocol Section:
NCT02184533